HYLOMORPH AG successfully raises 5.2M CHF during Series-B round

HYLOMORPH AG, a Wyss Zurich alumni and rapidly growing clinical-stage medtech startup with a history of national and international recognition, completed a CHF 5.2 million Series-B financing round. At the same time, the company attracted CHF 0.9 million in new non-dilutive funding.

This financing round aims at safely bringing the company to FDA and CE mark approval of its product portfolio, beginning with the blockbuster Hylomate®.

Recommended News

Sign up for our newsletter!

For newsletter distribution, your email address will be processed by a GDPR-certified service provider. Further information can be found in our privacy policy.